Azacitidine Is Effective in Patients with Low Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry

被引：0

作者：

Garcia, Regina ^{[1
]}

de Miguel, Dunia ^{[2
]}

Bernal, Maria-Teresa ^{[3
]}

Tormo, Mar ^{[4
]}

Sanz, Guillermo ^{[5
]}

de Paz, Raquel ^{[6
]}

Figueredo, Antonio ^{[7
]}

Amutio, Maria E. ^{[8
]}

Guzman, Jose L. ^{[9
]}

机构：

[1] Hosp Virgen Victoria, Malaga, Spain

[2] Hosp Univ Guadalaja, Madrid, Spain

[3] PETHEMA Grp, Oviedo, Spain

[4] Hosp Clin, Valencia, Spain

[5] Hosp Univ La Fe, Valencia, Spain

[6] Hosp Univ La Paz, Madrid, Spain

[7] Hosp Virgen Macarena, Seville, Spain

[8] Hosp Cruces, Bilbao, Spain

[9] Hosp SAS Jerez de la Frontera, Jerez de la Frontera, Spain

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1462 / 1462

页数：1

共 50 条

[31] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
Randhawa, Jasleen K.
Jabbar, Kausar Jabeen
Kadia, Tapan
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval
Kantarjian, Hagop M.
Cortes, Jorge E.
Hearn, Katherine
Bueso-Ramos, Carlos E.
Garcia-Manero, Guillermo
BLOOD, 2014, 124 (21)
[32] Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry.
Stauder, Reinhard
Smith, Alex
de Witte, Theo
Droste, Jackie
Fenaux, Pierre
Symeonidis, Argyris
Hellstrom-Lindberg, Eva
Sanz, Guillermo F.
Cermak, Jaroslav
Georgescu, Otilia
Germing, Ulrich
MacKenzie, Marius
Beyne-Rauzy, Odile
Malcovati, Luca
Bowen, David
BLOOD, 2010, 116 (21) : 1630 - 1630
[33] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Raza, Azra
Galili, Naomi
Mulford, Deborah
Smith, Scott E.
Brown, Gail L.
Steensma, David P.
Lyons, Roger M.
Boccia, Ralph
Sekeres, Mikkael A.
Garcia-Manero, Guillermo
Mesa, Ruben A.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
[34] Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study
Messa, Emanuela
Gioia, Daniela
Masiera, Elisa
Castiglione, Anna
Ceccarelli, Manuela
Salvi, Flavia
Danise, Paolo
Sanna, Alessandro
Allione, Bernardino
Balleari, Enrico
Poloni, Antonella
Cametti, Giovanni
Ferrero, Dario
Tassara, Rodolfo
Finelli, Carlo
Bonferroni, Margherita
Musto, Pellegrino
Saglio, Giuseppe
Levis, Alessandro
Santini, Valeria
HAEMATOLOGICA, 2019, 104 (01) : E4 - E8
[35] Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation
Daher, May
Lopez, Juliana Elisa Hidalgo
Randhawa, Jasleen K.
Jabbar, Kausar Jabeen
Pemmaraju, Naveen
Borthakur, Gautam
Kadia, Tapan M.
Konopleva, Marina
Kantarjian, Hagop M.
Cortes, Jorge E.
Hearn, Katherine P.
Reyes, Steven R.
Bueso-Ramos, Carlos E.
Garcia-Manero, Guillermo
BLOOD, 2016, 128 (22)
[36] A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
Eunice S Wang
Roger M Lyons
Richard A Larson
Sunil Gandhi
Delong Liu
Carmen Matei
Bart Scott
Kuolung Hu
Allen S Yang
Journal of Hematology & Oncology, 5
[37] A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
Wang, Eunice S.
Lyons, Roger M.
Larson, Richard A.
Gandhi, Sunil
Liu, Delong
Matei, Carmen
Scott, Bart
Hu, Kuolung
Yang, Allen S.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
[38] Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
Platzbecker, Uwe
Germing, Ulrich
Giagounidis, Aristoteles
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin Tina
Ottmann, Oliver
Radsak, Markus
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn
Zhang, Xiaosha
Laadem, Abderrahmane
Sherman, Matthew L.
Attie, Kenneth M.
BLOOD, 2015, 126 (23)
[39] Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study
Giagounidis, Aristoteles
Platzbecker, Uwe
Germing, Ulrich
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin Tina
Ottmann, Oliver
Radsak, Markus
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn
Zhang, Xiaosha
Laadem, Adberrahmane
Sherman, Matthew L.
Attie, Kenneth M.
BLOOD, 2015, 126 (23)
[40] Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial
Garcia-Manero, Guillermo
Yee, Karen W. L.
Hernandez, Francisca
Della Porta, Matteo Giovanni
Paolini, Stefania
Ahn, Seo-Yeon
Santini, Valeria
Fenaux, Pierre
Suzuki, Takahiro
Sekeres, Mikkael A.
He, Jun
Li, Jerry
Barkalifa, Ronit
Vigil, Carlos E.
Prebet, Thomas
de Menezes, Daniel Lopes
Burnett, Joseph
Komrokji, Rami S.
Giagounidis, Aristoteles
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →